SA109300315B1 - بروتينات ارتباط مستقبل إنترلوكين-21 - Google Patents

بروتينات ارتباط مستقبل إنترلوكين-21 Download PDF

Info

Publication number
SA109300315B1
SA109300315B1 SA109300315A SA109300315A SA109300315B1 SA 109300315 B1 SA109300315 B1 SA 109300315B1 SA 109300315 A SA109300315 A SA 109300315A SA 109300315 A SA109300315 A SA 109300315A SA 109300315 B1 SA109300315 B1 SA 109300315B1
Authority
SA
Saudi Arabia
Prior art keywords
binding
ser
leu
gly
thr
Prior art date
Application number
SA109300315A
Other languages
Arabic (ar)
English (en)
Inventor
بلوم ليرد
جيل دافيندر
فوجميستر يوليا
يونج . ديبورا ايه
لو، ديفيد
فالج -أرتشير، فيا
Original Assignee
ميدلمون ليمتد
ويث
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA109300315(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ميدلمون ليمتد, ويث filed Critical ميدلمون ليمتد
Publication of SA109300315B1 publication Critical patent/SA109300315B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SA109300315A 2008-05-23 2009-05-23 بروتينات ارتباط مستقبل إنترلوكين-21 SA109300315B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
SA109300315B1 true SA109300315B1 (ar) 2012-08-28

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
SA109300315A SA109300315B1 (ar) 2008-05-23 2009-05-23 بروتينات ارتباط مستقبل إنترلوكين-21

Country Status (20)

Country Link
US (2) US8163884B2 (https=)
EP (1) EP2297199A1 (https=)
JP (1) JP2011523849A (https=)
KR (1) KR20110040773A (https=)
CN (1) CN102105491A (https=)
AR (1) AR071885A1 (https=)
AU (1) AU2009248809A1 (https=)
CA (1) CA2724915A1 (https=)
CL (1) CL2009001284A1 (https=)
CO (1) CO6382184A2 (https=)
IL (1) IL209328A0 (https=)
MX (1) MX2010012811A (https=)
MY (1) MY149448A (https=)
NZ (1) NZ589330A (https=)
PE (1) PE20100141A1 (https=)
RU (1) RU2010152690A (https=)
SA (1) SA109300315B1 (https=)
TW (1) TW201000129A (https=)
WO (1) WO2009143523A1 (https=)
ZA (1) ZA201008335B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
JP6027744B2 (ja) * 2009-12-25 2016-11-16 積水メディカル株式会社 ヒトインスリン測定方法及び測定試薬
US8846603B2 (en) * 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
KR100743640B1 (ko) 1999-03-09 2007-07-27 지모제넥틱스, 인코포레이티드 신규한 사이토킨 ｚａｌｐｈａ 11 리간드
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
EP1787997A1 (en) 2000-05-11 2007-05-23 Genetics Institute, LLC MU-1, member of the cytokine receptor family
ES2334338T3 (es) 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
DK1531850T3 (da) 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7314623B2 (en) 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
CA2518854A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
EP1670501A2 (en) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
EP1753458A4 (en) 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
RU2007102287A (ru) 2004-08-05 2008-09-10 Вайет (Us) Антагонисты активности рецептора интерлейкина-21
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
CN102105491A (zh) 2011-06-22
US20090298167A1 (en) 2009-12-03
US20120264919A1 (en) 2012-10-18
CL2009001284A1 (es) 2009-11-27
WO2009143523A1 (en) 2009-11-26
US8163884B2 (en) 2012-04-24
AU2009248809A1 (en) 2009-11-26
PE20100141A1 (es) 2010-02-22
EP2297199A1 (en) 2011-03-23
CO6382184A2 (es) 2012-02-15
ZA201008335B (en) 2014-04-30
CA2724915A1 (en) 2009-11-26
AR071885A1 (es) 2010-07-21
KR20110040773A (ko) 2011-04-20
MX2010012811A (es) 2011-05-19
JP2011523849A (ja) 2011-08-25
IL209328A0 (en) 2011-01-31
MY149448A (en) 2013-08-30
RU2010152690A (ru) 2012-06-27
TW201000129A (en) 2010-01-01
NZ589330A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
US20240132603A1 (en) Ccr8 antibody and application thereof
CN106939050B (zh) 抗pd1和cd19双特异性抗体及其应用
CN111171150A (zh) 抗人tslp抗体及其用途
SA109300315B1 (ar) بروتينات ارتباط مستقبل إنترلوكين-21
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
US20200002415A1 (en) Binding molecules specific for fcgamma riia and uses thereof
CN102089326A (zh) 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CN116133684B (zh) 抗人nr1抗体衍生物
TW202546009A (zh) 抗hk2嵌合抗原受體(car)
KR20110021919A (ko) 인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
CN112375146B (zh) 检测Anti-CD19 CAR表达水平的抗独特性抗体及其应用
TW202547877A (zh) 位點特異性Notch活化分子及其用途
KR20160125965A (ko) 신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
US20220411523A1 (en) Molecule capable of binding to human 4-1bb and its application thereof
CN115947855B (zh) 抗cd24抗体的制备及其用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
TWI795872B (zh) 抗gm2ap抗體及其應用
CN120865418B (zh) 抗ror1抗体及其应用
CN115521378B (zh) Pd-l1抗体及其用途
KR102955674B1 (ko) 신규한 결합 분자 및 이의 용도
WO2020248156A1 (zh) Pd-l1靶向结合剂及其用途
US20240409617A1 (en) Multispecific coronavirus antibodies
WO2024094159A1 (zh) 靶向人源ror1的单域抗体